The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine Tumors
Open accessAbstract
UNLABELLED: Radiolabeled somatostatin analogs represent valuable tools for both in vivo diagnosis and therapy of neuroendocrine tumors (NETs) because of the frequent tumoral overexpression of somatostatin receptors (sst). The 2 compounds most often used in functional imaging with PET are (68)Ga-DOTATATE and (68)Ga-DOTATOC. Both ligands share a quite similar sst binding profile. However, the in vitro affinity of (68)Ga-DOTATATE in binding the sst subtype 2 (sst2) is approximately 10-fold higher than that of (68)Ga-DOTATOC. This difference may affect their efficiency in the detection of NET lesions because it is the sst2 that is predominantly overexpressed in NET. We thus compared the diagnostic value of PET/CT with both radiolabeled somatostatin analogs ((68)Ga-DOTATATE and (68)Ga-DOTATOC) in the same NET patients. METHODS: Forty patients with metastatic NETs underwent (68)Ga-DOTATOC and (68)Ga-DOTATATE PET/CT as part of the work-up before prospective peptide receptor radionuclide therapy. The performance of both imaging methods was analyzed and compared for the detection of individual lesions per patient and for 8 defined body regions. A region was regarded positive if at least 1 lesion was detected in that region. In addition, radiopeptide uptake in terms of the maximal standardized uptake value (SUVmax) was compared for concordant lesions and renal parenchyma. RESULTS: Seventy-eight regions were found positive with (68)Ga-DOTATATE versus 79 regions with (68)Ga-DOTATOC (not significant). Overall, however, significantly fewer lesions were detected with (68)Ga-DOTATATE than with (68)Ga-DOTATOC (254 vs. 262, P < 0.05). Mean (68)Ga-DOTATATE SUVmax across all lesions was significantly lower than (68)Ga-DOTATOC (16.0 ± 10.8 vs. 20.4 ± 14.7, P < 0.01). Mean SUVmax for renal parenchyma was not significantly different between (68)Ga-DOTATATE and (68)Ga-DOTATOC (12.7 ± 3.0 vs. 13.2 ± 3.3). CONCLUSION: (68)Ga-DOTATOC and (68)Ga-DOTATATE possess a comparable diagnostic accuracy for the detection of NET lesions, with (68)Ga-DOTATOC having a potential advantage. The approximately 10-fold higher affinity for the sst2 of (68)Ga-DOTATATE does not prove to be clinically relevant. Quite unexpectedly, SUVmax of (68)Ga-DOTATOC scans tended to be higher than their (68)Ga-DOTATATE counterparts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT
Martin Bland, J., & Altman, D. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90837-8 · Cited by 47,965
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Reubi, J. C., Schär, J.-C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., & Mäcke, H. R. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050034 · Cited by 1,127
Gabriel, M., Decristoforo, C., Kendler, D., Dobrozemsky, G., Heute, D., Uprimny, C., Kovacs, P., Von Guggenberg, E., Bale, R., & Virgolini, I. J. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.035667 · Cited by 1,010
Reubi, J., Waser, B., Schaer, J.-C., & Laissue, J. A. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100541 · Cited by 657
Reubi, J. C., & Waser, B. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1184-3 · Cited by 592
Classification and nomenclature of somatostatin receptors
Hoyer, D., Bell, G. I., Berelowitz, M., Epelbaum, J., Feniuk, W., Humphrey, P. P. A., O'Carroll, A.-M., Patel, Y. C., Schonbrunn, A., Taylor, J. E., et al. (1995) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)88988-9 · Cited by 570
Buchmann, I., Henze, M., Engelbrecht, S., Eisenhut, M., Runz, A., Schäfer, M., Schilling, T., Haufe, S., Herrmann, T., & Haberkorn, U. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0450-1 · Cited by 506
Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumours
Plöckinger, U., Rindi, G., Arnold, R., Eriksson, B., Krenning, E. P., de Herder, W. W., Goede, A., Caplin, M., Öberg, K., Reubi, J. C., et al. (2004) · Neuroendocrinology · doi:10.1159/000085237 · Cited by 477
Kayani, I., Bomanji, J. B., Groves, A., Conway, G., Gacinovic, S., Win, T., Dickson, J., Caplin, M., & Ell, P. J. (2008) · Cancer · doi:10.1002/cncr.23469 · Cited by 477
[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients
Kwekkeboom, D. J., Bakker, W. H., Kooij, P. P., Konijnenberg, M. W., Srinivasan, A., Erion, J. L., Schmidt, M. A., Bugaj, J. L., de Jong, M., & Krenning, E. P. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100574 · Cited by 471
Bodei, L., Cremonesi, M., Ferrari, M., Pacifici, M., Grana, C. M., Bartolomei, M., Baio, S. M., Sansovini, M., & Paganelli, G. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0778-1 · Cited by 428
Valkema, R., Pauwels, S. A., Kvols, L. K., Kwekkeboom, D. J., Jamar, F., de Jong, M., Barone, R., Walrand, S., Kooij, P. P. M., Bakker, W. H., et al. (2005) · PubMed · Cited by 332
Binderup, T., Knigge, U., Loft, A., Mortensen, J., Pfeifer, A., Federspiel, B., Hansen, C. P., Højgaard, L., & Kjaer, A. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.069765 · Cited by 279
de Jong, M., Breeman, W. A., Bakker, W., Kooij, P. P. M., Bernard, B. F., Hofland, L. J., Visser, T. J., Srinivasan, A., Schmidt, M. A., Erion, J. L., et al. (1998) · PubMed · Cited by 209
Wild, D., Mäcke, H. R., Waser, B., Reubi, J. C., Ginj, M., Rasch, H., Müller-Brand, J., & Hofmann, M. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1697-4 · Cited by 192
Esser, J. P., Krenning, E. P., Teunissen, J. J. M., Kooij, P. P. M., van Gameren, A. L. H., Bakker, W. H., & Kwekkeboom, D. J. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0172-9 · Cited by 179
(2005) · PubMed · Cited by 156
Molecular imaging in neuroendocrine tumors: Molecular uptake mechanisms and clinical results
Koopmans, K. P., Neels, O. N., Kema, I. P., Elsinga, P. H., Links, T. P., de Vries, E. G. E., & Jager, P. L. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.02.009 · Cited by 151
Antoch, G., Kuehl, H., Kanja, J., Lauenstein, T. C., Schneemann, H., Hauth, E., Jentzen, W., Beyer, T., Goehde, S. C., & Debatin, J. F. (2004) · Radiology · doi:10.1148/radiol.2303021287 · Cited by 144
Self-citationVelikyan, I., Sundin, A., Eriksson, B. K., Lundqvist, H., Sørensen, J. C. H., Bergström, M., & Långström, B. (2010) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2009.11.008 · Cited by 140
Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues
Rolleman, E. J., Melis, M. L., Valkema, R., Boerman, O. C., Krenning, E. P., & de Jong, M. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1282-y · Cited by 131
Koukouraki, S. I., Strauss, L. G., Georgoulias, V., Schuhmacher, J., Haberkorn, U., Karkavitsas, N. S., & Dimitrakopoulou‐Strauss, A. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-0006-1 · Cited by 127
Boy, C., Heusner, T. A., Poeppel, T. D., Redmann-Bischofs, A., Unger, N., Jentzen, W., Brandau, W., Mann, K., Antoch, G., Bockisch, A., et al. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1760-x · Cited by 125
Self-citationWhole-Body Positron Emission Tomography—CT: Optimized CT Using Oral and IV Contrast Materials
Antoch, G., Freudenberg, L. S., Stattaus, J., Jentzen, W., Müeller, S., Debatin, J. F., & Bockisch, A. (2002) · American Journal of Roentgenology · doi:10.2214/ajr.179.6.1791555 · Cited by 117
Self-citationForrer, F., Uusij�rvi, H., Waldherr, C., Cremonesi, M., Bernhardt, P., Mueller‐Brand, J., & Maëcke, H. R. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1553-6 · Cited by 108
Storch, D., Béhé, M. P., Walter, M. A., Chen, J., Powell, P., Mikołajczak, R., & Mäcke, H. R. (2005) · PubMed · Cited by 92
Rodrigues, M., Traub‐Weidinger, T., Li, S., Ibi, B., & Virgolini, I. J. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-0020-3 · Cited by 49
Cited by
Sundin, A., Arnold, R., Baudin, E., Cwikla, J. B., Eriksson, B., Fanti, S., Fazio, N., Giammarile, F., Hicks, R. J., Kjaer, A., et al. (2017) · Neuroendocrinology · doi:10.1159/000471879 · Cited by 501
Howe, J. R., Cardona, K., Fraker, D. L., Kebebew, E., Untch, B. R., Wang, Y.-Z., Law, C. H., Liu, E. H., Kim, M. K., Menda, Y., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000846 · Cited by 376
Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors
Hope, T. A., Bergsland, E. K., Bozkurt, M. F., Graham, M., Heaney, A. P., Herrmann, K., Howe, J. R., Kulke, M. H., Kunz, P. L., Mailman, J., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.202275 · Cited by 363
Prospective of 68Ga-Radiopharmaceutical Development
Velikyan, I. (2014) · Theranostics · doi:10.7150/thno.7447 · Cited by 336
Radiopharmaceuticals and their applications in medicine
Zhang, S., Wang, X., Gao, X., Chen, X., Li, L., Li, G., Liu, C., Miao, Y., Wang, R., & Hu, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02041-6 · Cited by 284
Metadata
- Authors
- Poeppel, T. D., Binse, I., Petersenn, S., Lahner, H., Schott, M., Antoch, G., Brandau, W., Bockisch, A., & Boy, C.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2011-11-09
- Volume
- 52
- Issue
- 12
- Pages
- 1864-1870
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2108035027
- Cited by
- 346
- References
- 28
- FWCI
- 11.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.